Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Add filters

Year range
Indian J Cancer ; 2012 Jul-Sept; 49(3): 266-271
Article in English | IMSEAR | ID: sea-144584


Context: Antracycline-Cyclophosphamide (AC) along with Paclitaxel/Docetaxel, either in combination or sequential regimens, is showing superior results than Anthracycline-containing regimens. Aims: This study was designed to determine whether adding Paclitaxel to a standard adjuvant chemotherapy regimen AC for breast cancer patients would prolong the time to recurrence and survival. Settings and Design: Randomized, prospective, open-labeled, single-institutional study. Materials and Methods: Fifty stage II breast cancer patients accruing 25 patients in each arm, treated between July 2007 and January 2010, were included in the study. Initial surgical treatment was Modified Radical Mastectomy. Systemic therapy was to have begun within 4-6 weeks of the patient's surgery. In the control arm, all the patients were treated with six cycles of adjuvant chemotherapy with AC regimen repeated at an interval of 3 weeks. For the study arm, the patients received adjuvant chemotherapy with three cycles of AC regimen followed by three cycles of Paclitaxel, repeated at an interval of 3 weeks. All the patients of both the arms received locoregional external beam radiotherapy (EBRT) after the entire course of chemotherapy. All the hormone receptor-positive patients received Tamoxifen. Statistical Analysis Used: Statistical analysis was performed using the chi-square test and the Kaplan Meier survival analysis with the log-rank (Mantel-Cox) test. Results: Adding Paclitaxel to AC resulted in a statistically significant disease-free survival. The overall survival was also improved significantly. The toxicity profile in both the arms was comparable. Conclusions: In early and node-positive breast cancer, the addition of three cycles of Paclitaxel after completion of three cycles of AC improves the disease-free and overall survival.

Anthracyclines/administration & dosage , Breast Neoplasms/drug therapy , Breast Neoplasms/surgery , Chemotherapy, Adjuvant/methods , Chemotherapy, Adjuvant/statistics & numerical data , Clinical Protocols , Cyclophosphamide/administration & dosage , Drug Combinations/administration & dosage , Female , Humans , Paclitaxel/administration & dosage , Taxoids/administration & dosage , Treatment Outcome
Article in English | IMSEAR | ID: sea-167436


Primary squamous cell carcinoma of the kidney is a rare clinical entity. Primary squamous cell carcinoma is more frequently reported in urinary bladder and male urethra than in kidney. Primary renal squamous cell carcinoma (RSCC) accounts for less than 5% of urothelial tumours in urinary system. Very few cases of primary squamous cell carcinoma of kidney have been reported in the world literature. Only forty-six cases over forty four years had been reported from Mayo Clinic. These neoplasms are highly aggressive and locally advanced or metastatic at the time of presentation. Here we report such a case of primary squamous cell carcinoma of kidney in a 50-year-old lady at a locally recurrent stage with fistulous tract formation. Palliative radiotherapy came out to be a good clinical modality even in locally recurrent stage in this patient.